Earnings Watch | Can Asieris' commercialization 2.0 pivot find a way out of its RMB 419M net loss?

Recently, Asieris Pharmaceuticals (stock code: 688176.SH) released its 2025 performance forecast. This report card serves as a mirror, reflecting the typical survival status of Chinese innovative pharmaceutical companies.

In 2025, Asieris achieved operating revenue of RMB 277 million, representing a year-on-year increase of 37.49%, demonstrating a steady commercial ramp-up capability. However, the net loss attributable to the parent company of RMB 419 million, with the loss margin expanding year-on-year, also highlights the substantial costs associated with innovative drug research and development as well as market development. Previously, the 2025 semi-annual report revealed that Asieris' research and development investment accounted for as high as 89.44% of its operating revenue.

Asieris is strategically leveraging its portfolio of established products. For instance, Neratinib Maleate Tablets (OUYOUBI®) and Pazopanib Tablets (DIPAITE®) became the primary sales drivers in 2025.

However, this merely represents defending its existing business foundation. The true potential for commercial growth ultimately hinges on the launch timelines and global expansion outcomes of core innovative products such as APL-1702.

In 2025, the operating revenue of RMB 277 million was primarily contributed by Neratinib Maleate Tablets (OUYOUBI®) and Pazopanib Tablets (DIPAITE®).

These two products, having commenced their first full year of commercialization in 2024, achieved a sales breakthrough in 2025 and are expected to continue growing.

Taking OUYOUBI® as an example, approved in September 2023, it is the first generic version of Neratinib Maleate Tablets launched in China. Its approved indication is for the extended adjuvant treatment of adult patients with early-stage human epidermal growth factor receptor 2-positive breast cancer following adjuvant therapy containing trastuzumab.

Currently, only two players are competing in this segment of the Chinese market: the original manufacturer, Puma Biotechnology, and Asieris, indicating relatively substantial market potential.

A research report from Southwest Securities previously projected that revenue in sample hospitals could reach RMB 100 million in 2024. Assuming a fivefold multiplier for the total Chinese market, this would correspond to nearly RMB 500 million in nationwide sales. If Asieris can capture 40% to 50% of this market share, the annual revenue from this single product could potentially reach the RMB 250 million level by 2027.

More noteworthy is that in 2025, Asieris introduced Eribulin Mesylate Injection (OUNALIN®) and rapidly achieved first prescriptions in multiple cities.

On March 27, 2025, Xiling Lab and Asieris announced a collaboration to jointly advance the research, development, and commercialization of anti-tumor drugs, based on the late-stage breast cancer treatment Eribulin Mesylate Injection. As a key aspect of this cooperation, Xiling Lab had obtained the production approval for Eribulin in China and granted Asieris the exclusive commercialization rights for the product in the Chinese market.

In September 2025, Asieris announced that first prescriptions for Eribulin Mesylate Injection had been made in multiple cities, including Yancheng, Xuzhou, Xi'an, Chengdu, and Harbin.

This signifies that in the field of breast cancer treatment, whether for early-stage adjuvant therapy or late-stage treatment, Asieris now possesses a commercialized product portfolio.

If the existing sales varieties represent defending its established business foundation, then Asieris is decidedly ambitious regarding another product, APL-1702.

Currently, treatment for patients with high-grade cervical precancerous lesions primarily relies on traditional surgical methods. The most common procedures include loop electrosurgical excision procedure and cold knife conization, with no non-surgical treatment products yet available on the market.

Asieris responded on an investor interaction platform on December 26, 2025, stating that APL-1702 is the first non-surgical treatment product globally to achieve positive results in an international multi-center Phase III clinical trial. This product employs a drug-device combination photodynamic therapy, enabling a convenient see-and-treat outpatient model.

It has been disclosed that the Center for Drug Evaluation of the National Medical Products Administration has completed the technical review for APL-1702. Currently, Asieris is accelerating its marketing authorization review and approval process, while simultaneously initiating a series of commercialization preparations. These efforts include promoting the publication of clinical data to support updates to clinical guidelines and expert consensus, as well as conducting disease burden and policy research to address accessibility and payment affordability.

In the performance forecast, another bright spot came from the innovative Class 1 drug APL-2401. This highly selective FGFR2/3 inhibitor passed the National Medical Products Administration's 30-Working-Day Pathway in 2025, receiving clinical trial approval in just 22 working days, and quickly completed dosing of the first subject. Concurrently, the product has been approved for clinical trials in Australia, marking Asieris's deep integration into the global simultaneous development track even at the early research and development stage.

Furthermore, APL-2501, a CLDN6/9-targeting ADC drug candidate with significant anti-tumor activity, is also planned for an Investigational New Drug application submission by mid-2026.

While revenue increased, the net loss of RMB 419 million drew market attention. Asieris stated in its announcement that the primary reasons for the expanded loss were that its core products are still under development or undergoing marketing authorization review, maintaining a consistently high level of research and development investment, as well as investments made to steadily advance the upgrade of its commercialization system and actively prepare for the commercialization of new products.

The 2025 semi-annual report revealed that Asieris' research and development investment accounted for as high as 89.44% of its operating revenue. Behind this high research and development expenditure lies the challenge of performance growth facing Asieris. Before innovative products are launched and begin scaling up, the two generic drugs, Neratinib Maleate Tablets and Pazopanib Tablets, bear the crucial responsibility of providing cash flow and sustaining the operation of the commercialization system.

The innovative products that will determine Asieris's future potential have also encountered research and development setbacks.

In 2024, a randomized, double-blind, controlled, multi-center pivotal clinical trial evaluating the combination of the investigational product APL-1202 with chemotherapeutic instillation for the treatment of intermediate and high-risk non-muscle invasive bladder cancer recurring after chemotherapeutic instillation, although showing a certain trend towards superiority in some patient subgroups, did not meet its primary endpoint.

Consequently, Asieris decided to terminate further development of the APL-1202 combination with chemotherapeutic instillation for this indication, resulting in nearly RMB 130 million in research and development investment yielding no return.

Addressing the trial termination, Pan Ke, Founder and Chairman of Asieris, stated at a media briefing, "This setback in one clinical trial does not signify the termination of the entire development of the 1202 program, nor does it shake our resolve in research and development for urologic oncology treatments."

According to his analysis, the failure stemmed from a deviation in the literature estimation regarding the efficacy of existing chemotherapeutic instillation at the time of the clinical trial design.

At that time, Asieris was still conducting two other clinical trials for APL-1202. According to its 2025 semi-annual report, existing data from the study of APL-1202 monotherapy for untreated intermediate-risk non-muscle invasive bladder cancer showed similar recurrence-free proportion rates between the APL-1202 monotherapy group and the chemotherapeutic instillation group. Furthermore, a Phase II clinical trial of APL-1202 in combination with tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer had generated positive efficacy signals.

Asieris also stated in its financial report that it is actively seeking overseas partners to advance the global clinical development of APL-1202. It has convened a meeting with United States clinical experts to discuss subsequent development directions and will actively communicate with regulatory authorities regarding later-stage clinical study plans, laying an important foundation for global development.

At the beginning of 2026, Asieris appointed Dr. Liu Ningshu, who has 25 years of experience in the oncology research field, as Chief Scientific Officer. Having served for over 20 years at Bayer's German headquarters and possessing global research and development experience from Fosun Pharma, her arrival is not merely to fill a vacancy, but to build an innovative drug technology platform meeting international standards.

Currently, the competition among Chinese innovative drug companies has evolved from simply spending money to advance programs to a comprehensive contest encompassing deepened research and development, internationalization, and commercialization.

The addition of Dr. Liu Ningshu could potentially accelerate the translation speed of Asieris's early-stage research pipeline.

From this perspective, Asieris, which focuses on the fields of genitourinary tract tumors and women's health, is currently in a critical transitional phase, shifting from being research and development-driven towards an integrated research and development, production, and marketing model. As early as 2020, upon completing its Series C financing, Pan Ke stated, "After ten years of accumulation, 2020 will be a year of rapid development for Asieris, with multiple projects nearing completion of clinical trials or filing for new drug certificates. Asieris will also embark on a new journey, formally transitioning from a research and development-focused company into a pharmaceutical company integrating research and development, production, and marketing, bringing innovative treatments and better therapeutic options to patients as soon as possible."

For Asieris itself, this remains an endurance race requiring attention to speed. Losses are still an objective reality that must be confronted. In terms of cultivating its product pipeline and designing its commercialization landscape, the company is actively working on how to continue leveraging its product portfolio effectively within its focused areas of genitourinary tract tumors and women's health.

In particular, the market penetration of APL-1702 following its future launch, as well as the output of competitive drug candidates from its early-stage research platform in areas such as antibody-drug conjugates and in-situ bladder tumor model technology, remain to be seen, and their realization will require continued patience.